ODYSSEY THERAPEUTICS INC (ODTX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-16
$17.17-2.28%
Close 2026-10-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-16
Research Workspace
Put ODTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisThis stock is volatile — it swings about 4% on a typical day and fell roughly 42% in its worst 12-month stretch.
View RiskODTX’s case rests on advancing OD-001 and OD-002 through clinical development. The desk lacks earnings history, so revenue growth and acceleration remain unverified. Trial extensions support that development effort, but no earnings release is recorded. No clean valuation multiple is available, and the desk says price is roughly in line with forecast growth. Management is behind on a stated commitment, and the model puts next-quarter miss probability near 66%. The sharp single-session drop may signal repricing of the ownership case. Peer multiples imply a price about 58% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-16. ODTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering ODTX (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for ODTX in the last 4 months.
Continue this research
Compare ODTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ODTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-16. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ODTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance clinical development of OD-001 and OD-002
Extended trials support advancement of clinical development objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-16. EPS is implied from price ÷ P/E. Not investment advice.
Current $17.17
The last 12 months of price, then the range of analyst 12-month targets from today’s $17.17.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
